# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Oppenheimer analyst Jeff Jones downgrades Seres Therapeutics (NASDAQ:MCRB) from Outperform to Perform.
Canaccord Genuity analyst John Newman maintains Seres Therapeutics (NASDAQ:MCRB) with a Buy and lowers the price target from...
Seres anticipates capital infusions, including an upfront payment, enabling the Company to fully retire its debt and extend i...
Oppenheimer analyst Jeff Jones maintains Seres Therapeutics (NASDAQ:MCRB) with a Outperform and lowers the price target from...